Prognostic impact of 1q21 amplification in patients with
multiple myeloma treated by velcade, thalidomide and any
conventional chemotherapy

D 2007

Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy

NĚMEC, Pavel, Petr KUGLÍK, Vladimíra VRANOVÁ, Romana ZAORALOVÁ, Henrieta GREŠLIKOVÁ et. al.

Základní údaje

Originální název

Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy

Název česky

Prognostický význam amplifikace 1q21 u pacientů s mnohočetným myelomem léčených Velcadem, thalidomidem a konvenční chemoterapií

Autoři

NĚMEC, Pavel (203 Česká republika), Petr KUGLÍK (203 Česká republika), Vladimíra VRANOVÁ (703 Slovensko), Romana ZAORALOVÁ (203 Česká republika), Henrieta GREŠLIKOVÁ (703 Slovensko), Alexandra OLTOVÁ (203 Česká republika), Hana FILKOVÁ (203 Česká republika), Petra VIDLÁKOVÁ (203 Česká republika), Jana SMEJKALOVÁ (203 Česká republika) a Roman HÁJEK (203 Česká republika, garant)

Vydání

Volume 21, Supplement 1. Neuveden, Blood Reviews, od s. 131-131, 1 s. 2007

Nakladatel

Elsevier

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

Genetika a molekulární biologie

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.922

Kód RIV

RIV/00216224:14110/07:00022792

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000249533100218

Klíčová slova anglicky

multiple myeloma; 1q21 amplification; velcade; thalidomide; fluorescence in situ hybridisation;

Štítky

1q21 amplification, fluorescence in situ hybridisation, multiple myeloma, Thalidomide, Velcade

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 3. 2009 11:06, Mgr. Pavel Němec, Ph.D.

Anotace

ORIG CZ

V originále

Introduction Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). This study was aimed at comparison of prognostic impact of 1q21 gain in three selected groups of patients with diagnosed MM based on treatment regiment. Materials and Methods Plasma cells were identified by cytoplasmic light chain fluorescence in situ hybridisation (cIg-FISH), 1q21 amplification (Amp1q21) utilizing the 1q21/1p36 DNA probe. Amp1q21 was taken such as detection of one or more additional signals of 1q21. Cut-off level for Amp1q21 was established to 20% of total amount of cells with additional signals detected. Patients with Amp1q21 and patients lacking Amp1q21 of each group were statistically correlated with clinical parameters. Up to date we have carried out analysis of 66 (n=66) patients. This group of patients with median of follow up 8,6 months (range: 0,3-30,4) was divided according to the undergone therapy into 3 groups: "C-group" comprises 17 samples of patients treated by any conventional chemotherapy; "T-group" comprises 27 samples of patients treated by thalidomide; "V-group" comprises 22 samples of patients treated by Velcade. The response and other parameters such as time to progression (TTP) and overall survival (OS) were assigned by IMWG criteria. Results Amp1q21 was found in 62.1% of all 66 patients. Percentage of patients with Amp1q21 in C/T/V-groups were as follows: 64.7% / 40.7% / 86.4%, respectively. Clinical parameters valid for patients with Amp1q21 (listed in C/T/V order) were as follows: overall response rate (ORR) 42.8% / 83.3% / 50%; TTP 8.8 / 12.1 / 8.0 months; OS 16.1 / 6.6 / not yet reached for V-group. The same parameters valid for patients lacking Amp1q21: ORR 33.3% / 80% / 66.7%; TTP not yet reached for C-group / 8.2 / not yet reached for V-group; OS not yet reached for all groups. TTP median of patients with Amp1q21 vs. patients lacking 1q21 was: 8.2 vs. 12.1 months (p=0.269), OS 6.6 vs. not yet reached (p=0,072) in thalidomide group. We didn't find any other significant differences between patients with / without Amp1q21 and their parameters in V- and C-group. Conclusion Our results suggest that patients with Amp1q21 treated by thalidomide show a trend towards the worst prognosis based on overall survival. We are currently investigating whether or not our findings will be confirmed on a larger cohort of patients with longer follow-up. Supported by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre (LC06027), Masaryk University, Brno, Czech republic.

Česky

Práce pojednává o významu amplifikace 1q21 u pacientů s mnohočetným myelomem léčených Velcade, thalidomidem a konvenční chemoterapií

Návaznosti

LC06027, projekt VaV

Název: Univerzitní výzkumné centrum - Česká myelomová skupina (Akronym: LC MGUS)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Univerzitní výzkumné centrum - Česká myelomová skupina (URC - CMG)

Citovat

NĚMEC, Pavel, Petr KUGLÍK, Vladimíra VRANOVÁ, Romana ZAORALOVÁ, Henrieta GREŠLIKOVÁ, Alexandra OLTOVÁ, Hana FILKOVÁ, Petra VIDLÁKOVÁ, Jana SMEJKALOVÁ a Roman HÁJEK. Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy. In Blood Reviews. Volume 21, Supplement 1. Neuveden: Elsevier, 2007, s. 131-131. ISSN 0268-960X.

@inproceedings{726953,
   author = {Němec, Pavel and Kuglík, Petr and Vranová, Vladimíra and Zaoralová, Romana and Grešliková, Henrieta and Oltová, Alexandra and Filková, Hana and Vidláková, Petra and Smejkalová, Jana and Hájek, Roman},
   address = {Neuveden},
   booktitle = {Blood Reviews},
   edition = {Volume 21, Supplement 1},
   keywords = {multiple myeloma; 1q21 amplification; velcade; thalidomide; fluorescence in situ hybridisation;},
   language = {eng},
   location = {Neuveden},
   pages = {131-131},
   publisher = {Elsevier},
   title = {Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy},
   year = {2007}
}

TY  - JOUR
ID  - 726953
AU  - Němec, Pavel - Kuglík, Petr - Vranová, Vladimíra - Zaoralová, Romana - Grešliková, Henrieta - Oltová, Alexandra - Filková, Hana - Vidláková, Petra - Smejkalová, Jana - Hájek, Roman
PY  - 2007
TI  - Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy
PB  - Elsevier
CY  - Neuveden
KW  - multiple myeloma
KW  - 1q21 amplification
KW  - velcade
KW  - thalidomide
KW  - fluorescence in situ hybridisation;
N2  - Introduction Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). This study was aimed at comparison of prognostic impact of 1q21 gain in three selected groups of patients with diagnosed MM based on treatment regiment. Materials and Methods Plasma cells were identified by cytoplasmic light chain fluorescence in situ hybridisation (cIg-FISH), 1q21 amplification (Amp1q21) utilizing the 1q21/1p36 DNA probe. Amp1q21 was taken such as detection of one or more additional signals of 1q21. Cut-off level for Amp1q21 was established to 20% of total amount of cells with additional signals detected. Patients with Amp1q21 and patients lacking Amp1q21 of each group were statistically correlated with clinical parameters. Up to date we have carried out analysis of 66 (n=66) patients. This group of patients with median of follow up 8,6 months (range: 0,3-30,4) was divided according to the undergone therapy into 3 groups: "C-group" comprises 17 samples of patients treated by any conventional chemotherapy; "T-group" comprises 27 samples of patients treated by thalidomide; "V-group" comprises 22 samples of patients treated by Velcade. The response and other parameters such as time to progression (TTP) and overall survival (OS) were assigned by IMWG criteria. Results Amp1q21 was found in 62.1% of all 66 patients. Percentage of patients with Amp1q21 in C/T/V-groups were as follows: 64.7% / 40.7% / 86.4%, respectively. Clinical parameters valid for patients with Amp1q21 (listed in C/T/V order) were as follows: overall response rate (ORR) 42.8% / 83.3% / 50%; TTP 8.8 / 12.1 / 8.0 months; OS 16.1 / 6.6 / not yet reached for V-group. The same parameters valid for patients lacking Amp1q21: ORR 33.3% / 80% / 66.7%; TTP not yet reached for C-group / 8.2 / not yet reached for V-group; OS not yet reached for all groups. TTP median of patients with Amp1q21 vs. patients lacking 1q21 was: 8.2 vs. 12.1 months (p=0.269), OS 6.6 vs. not yet reached (p=0,072) in thalidomide group. We didn't find any other significant differences between patients with / without Amp1q21 and their parameters in V- and C-group. Conclusion Our results suggest that patients with Amp1q21 treated by thalidomide show a trend towards the worst prognosis based on overall survival. We are currently investigating whether or not our findings will be confirmed on a larger cohort of patients with longer follow-up. Supported by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre (LC06027), Masaryk University, Brno, Czech republic.
ER  -

NĚMEC, Pavel, Petr KUGLÍK, Vladimíra VRANOVÁ, Romana ZAORALOVÁ, Henrieta GREŠLIKOVÁ, Alexandra OLTOVÁ, Hana FILKOVÁ, Petra VIDLÁKOVÁ, Jana SMEJKALOVÁ a Roman HÁJEK. Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy. In \textit{Blood Reviews}. Volume 21, Supplement 1. Neuveden: Elsevier, 2007, s.~131-131. ISSN~0268-960X.

Podrobný výpis o publikaci